Isis reaches new highs on Phase I SMA drug data
This article was originally published in Scrip
Isis Pharmaceuticals has seen its fair share of stock price gains this year and the company closed up another 14.1% to reach a new high of $36.27 per share on 19 September on the news that children with spinal muscular atrophy in a Phase I study continued to show benefits up to 14 months after a single intrathecal injection with the two highest doses of ISIS-SMNRx.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.